NCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
Clinical Trials
23 trialsNCT03065387 2026-01-12
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04116541 2025-11-21
MegaMOST
Centre Leon Berard
Phase 2 Recruiting
NCT02079740 2025-09-30
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02070549 2025-02-13
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT06456138 2024-06-13
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Shanghai Chest Hospital
Phase 1/2 Not yet recruiting
NCT05071183 2024-04-02
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05876806 2023-11-30
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
Seoul St. Mary's Hospital
Phase 2 Unknown
NCT04801966 2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA Terminated
NCT01231594 2019-03-22
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Novartis
Phase 1 Completed
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT02939846 2018-09-14
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
GlaxoSmithKline
Phase 1 Withdrawn
NCT03543306 2018-06-01
Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation
Asan Medical Center
Phase 2 Unknown
NCT01192165 2017-11-13
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
GlaxoSmithKline
Phase 1 Completed
NCT01371487 2017-11-13
GSK1120212 Food-effect Study
GlaxoSmithKline
Phase 1 Completed
NCT01387204 2017-11-13
Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212
GlaxoSmithKline
Phase 1 Completed
NCT01416337 2017-11-13
Absolute Bioavialability of GSK1120212
GlaxoSmithKline
Phase 1 Completed
NCT01647659 2017-11-13
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation
GlaxoSmithKline
Phase 1 Completed
NCT01658553 2017-11-13
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212
GlaxoSmithKline
Phase 1 Completed
NCT01248858 2017-05-09
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.
GlaxoSmithKline
Phase 1 Terminated
NCT02292732 2016-01-26
A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Withdrawn
NCT01231581 2013-09-26
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
GlaxoSmithKline
Phase 2 Completed